Gert STORM

Gert Storm – Department of Pharmaceutics – Utrecht Institute for Pharmaceutical Sciences

Position Field Publications
Citations
h-index

(Google Scholar)

Date
Prof Pharmaceutics 498 16626 66 December 1 2016

 

Gert Storm is professor at the Department of Pharmaceutics (80% employment) focused on the design and application of targeted nanomedicines, and particularly well-recognised as expert on liposomal drug formulations. He obtained his Ph.D. degree in 1987 at the Utrecht University with a thesis on the use of liposomes as drug carriers in cancer chemotherapy. In 1988-1989 he was a visiting scientist at Liposome Technology Inc. in Menlo Park, USA, and visiting assistant professor at the School of Pharmacy, UCSF, San Francisco. In 1990-1991 he was senior research scientist at Pharma Bio-Research Consultancy B.V. in Zuidlaren, The Netherlands. During this period he contributed to the design, co-ordination and evaluation of clinical pharmacological studies. In September 1991 he took up his position at the Utrecht University. In 1999, he was appointed adjunct professor and is now honorary professor (Biomacromolecular Drug Delivery) at the University of Copenhagen. In 2000, he was appointed as professor (Targeted Drug Delivery) at Utrecht University. From 2012 on, he is also professor (Targeted Therapeutics) at the MIRA institute of the University of Twente (20% employment). Furthermore, he also keeps a position (seconded) at the University Medical Center Utrecht (UMCU) (Division Imaging). He is included in the 2014, 2015 and 2016 lists of The World’s Most Influential Scientific Minds of Thomson Reuters (Highly Cited Researchers).

Research

The design, characterization and preclinical testing of liposomal formulations containing low or high molecular weight  therapeutic agents has always been a core activity in Gert Storm’s research. More recently, polymeric and stimuli-sensitive (e.g. to temperature) nanocarrier systems are receiving increasing research attention in his team. Additionally, the implementation of imaging-guided drug delivery protocols (using e.g. SPECT, MRI, PET) to optimize the performance of targeted nanomedicine formulations is a major research objective. Moreover, over the last decade, clinical translation of academic results has become a vital element of Prof. Storm’s ambition. He initiated translational research on the development of targeted drug formulations to improve the treatment of rheumatoid arthritis. Liposomal glucocorticoids appeared to show great promise at the preclinical level and was taken further by the creation of the spin-off company Enceladus Pharmaceuticals BV in 2005, founded to address issues like  pharmaceutical development, and scale-up according to GMP requirements, preclinical toxicology, toxicokinetics (for IND designation), clinical trial design, and intellectual property rights and licensing. At present, various versions of the liposomal corticosteroid platform technology have been evaluated in rheumatoid arthritis, multiple sclerosis, colitis and atherosclerosis patients. Clinical studies in prostate cancer and ophthalmological patients are being planned.  The  translational character of the research of Prof. Storm is further reflected by his involvement in public-private partnership projects from the EC (he was coordinator of the Integrated Project (FP6) Meditrans on targeted nanomedicine development, and partnering in NanoAthero, NAREB, PneumoNP, NanoMile  (all FP7)) and OcuTher and NABBA (both ITN, Horizon2020),  PI of the CTMM project HIFU-CHEM, director Program Drug Delivery of NanoNextNL, and partnering in projects of  TIPharma and AgentschapNL. Over the years, he also obtained significant funding for applied research from STW (e.g. for the development of radiopharmaceuticals for infection and inflammation imaging) and from several industries (e.g. Astellas, Astra Zeneca, Novartis). He collaborates with the spin-off company Cristal Therapeutics on the development of core-crosslinked polymeric micelles as targeted drug delivery system. He is one of the initiators (2007) and since then on the Board of the CLINAM (European Foundation for Clinical Nanomedicine) organization in Basel. Furthermore, he contributes to translational nanomedicine research performed at the University Medical Center Utrecht (UMCU), with the clinical testing of MRI-guided High Intensity Focused Ultrasound (MRI-HIFU) to induce triggered doxorubicin release from temperature-sensitive liposomes in breast tumors as currently  ongoing in the UMCU as a clinical translation project sponsored by the Dutch Cancer Society.

Selected publications

  1. Lammers T, Kiessling F, Ashford M, Hennink WE, Crommelin DJA and Storm G. Cancer nanomedicine: Is targeting our target? Nature Review Materials 1, 16069, 2016
  2. Hare Jl, Lammers T, Ashford MB, Puri S, Storm G, and Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews 2016, http://dx.doi.org/10.1016/j.addr.2016.04.025
  3. Crielaard BJ, Rijcken CJF, Quan L, van der Wal S, Altintas I, van der Pot M, Kruijtzer JAW, Liskamp RMJ, Schiffelers RM, van Nostrum CF, Hennink WE, Wang D, Lammers T, and Storm G. Glucocorticoid-loaded core-crosslinked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angewandte Chemie 51, 7254-7258 (2012)
  4. Lammers, S. Aime, W.E. Hennink, G. Storm*, F. Kiessling*, Theranostic nanomedicine, Accounts of Chemical Research, (2011), 44, 1029-38 (* shared senior authorship)
  5. Crielaard BJ, Yousefi A, Schillemans JP, Vermehren C, Buyens K, Braeckmans K, Lammers T, and Storm G. An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes. Journal of Controlled Release 156, 307-314, 2011.

Selected grants

  • OcuTher, Ocular delivery of drugs (ITN programme) (together with Prof. W. Hennink), €550,000/2016-2020.
  • Targeting eye inflammation. PhD Grant Singapore National Eye Centre (SNEC) (together with prof. T. Wong, SNEC), 2016-2020
  • KWF-STW project Drug delivery by sonoporation in childhood brain cancer (together with Prof. C. Moonen UMCU and Prof. G. Kaspers AMC) €568000/2016-2020
  • KWF: Image-guided targeted doxorubicin delivery with hyperthermia to optimize loco-regional control in breast cancer, the i-GO feasibility study (at UMCU, clinical follow-up of HIFU-CHEM), €500000/2016-2020
  • NABBA, Nanomedicines to overcome biological barriers (ITN programme) (together with prof. T. Lammers RWTH Aachen University),  €275000/2014-2018
  • STW project Nanomedicines targeting the multiple myeloma stroma alliance (together with Prof. R. Schiffelers UMCU), €620000/2014-2018
  • PROPER Alpe d’Huzes/KWF project: ‘Near-patient’ prostate cancer models for the assessment of disease prognosis and therapy response (together with Dr. G. van der Pluijm LUMC), €110000/2014-2018
  • PneumoNP EU-FP7 Collaborative Project: Nanotherapeutics to treat pneumonia (together with Dr. R. van Nostrum), €400000/2014-2018
  • NAREB EU-FP7 Collaborative Project: Nanotherapeutics against antibiotic-resistant bacteria (together with Dr. R. van Nostrum), €375000/2014-2018
  • NanoMile EU-FP7 Collaborative Project: Engineered nanomaterials and nanotoxicology (together with Dr. R. Kok), €300000/2013-2018
  • NanoNextNL Programme Drug Delivery, Director, 10M€/2012-2017
  • HIFU-CHEM, PI, 7M€, Triggered release of drugs from nanoparticles using high intensity focused ultrasound for tumour therapy/CTMM (The Center for Translational Molecular Medicine (together with Prof. W.Hennink),  €650,000/2011-2015
  • EU-FP6 Meditrans, Coordinator, Integrated Project Targeted Nanomedicine, 15M€/2007-2012